赫賽汀的用藥指證：

來源: 於 2015-05-25 07:42:58 [博客] [舊帖] [給我悄悄話] 本文已被閱讀：次

Indications

Adjuvant Breast Cancer

Herceptin is indicated for adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one high-risk feature*) breast cancer:

  • As part of a treatment regimen containing doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
  • With docetaxel and carboplatin
  • As a single agent following multi-modality anthracycline-based therapy

* High-risk is defined as ER/PR positive with one of the following features: tumor size >2 cm, age <35 years, or tumor grade 2 or 3.

Metastatic Breast Cancer

Herceptin is indicated:

  • In combination with paclitaxel for the first line treatment of HER2-overexpressing metastatic breast cancer
  • As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease
目前的研究結果：對於Her-2陽性的乳癌患者，輔助使用赫賽汀有助於延長生存，以及延緩/防止複發。

任何藥物都尤其副作用，赫賽汀的常見副作用是腹瀉，一些非特異的感冒樣症狀等，但比較嚴重（雖然不那麽常見）的副作用是心衰等心髒方麵的疾病，所以需要定期做心髒方麵的監測篩查。